Ask AI
ProCE Banner Activity

SAVE: Phase I/II Study of Oral Revumenib Plus Decitabine/Cedazuridine and Venetoclax in Cohort of Patients with Newly Diagnosed AML

Conference Coverage
Slideset

Results from the phase I/II SAVE study of the all-oral regimen of revumenib and decitabine/cedazuridine plus venetoclax demonstrate high activity with deep responses in older patients with newly diagnosed NPM1-mutant or KMT2A-rearranged AML who are not candidates for intensive chemotherapy.

Released: December 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner

Target Audience

This activity is intended for healthcare professionals who care for patients with malignant or nonmalignant hematologic disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with malignant or nonmalignant hematologic disorders

  • Evaluate new data on novel agents and therapeutic approaches for patients with malignant or nonmalignant hematologic disorders

  • Appraise how new trial findings might advance the treatment of patients with malignant or nonmalignant hematologic disorders in the future

  • Support informed shared decision-making for patients with malignant and nonmalignant hematologic disorders through accessible discussion of the potential clinical implications of recently presented data